INDEMNIFICATION AGREEMENTIndemnification Agreement • April 14th, 2021 • Organon & Co. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (this “Agreement”) is entered into as of , 2021 (the “Effective Date”) by and between Organon & Co., a Delaware corporation (the “Company”), and (the “Indemnitee”).
EMPLOYEE MATTERS AGREEMENT BY AND BETWEEN MERCK & CO., INC. AND ORGANON & CO. DATED AS OF _____, 2021Employee Matters Agreement • April 14th, 2021 • Organon & Co. • Pharmaceutical preparations
This EMPLOYEE MATTERS AGREEMENT dated as of [____], 2021, is by and between Merck & Co., Inc., a New Jersey corporation (“Merck”) and Organon & Co., a Delaware corporation (“Organon”) (each a “Party” and together, the “Parties”).
MERCK TO ORGANON TRANSITION SERVICES AGREEMENTOrganon Transition Services Agreement • April 14th, 2021 • Organon & Co. • Pharmaceutical preparations • New York
This Transition Services Agreement (this “Agreement”), dated as of [____], 2021 (the “Effective Date”) is entered into by and between Organon LLC, a Delaware limited liability company (“Organon”), and MSD International GmbH, a limited liability company organized under the laws of Switzerland (“Merck” and together with Organon, each a “Party” and collectively, the “Parties”).
TAX MATTERS AGREEMENT by and between MERCK & CO., INC. and ORGANON & CO.Tax Matters Agreement • April 14th, 2021 • Organon & Co. • Pharmaceutical preparations • Delaware
This Tax Matters Agreement (the “Agreement”) is entered into as of the [ ] day of [June, 2021], by and between Merck & Co., Inc. (“Merck”), a New Jersey corporation, and Organon & Co. (“Organon” and, together with Merck, the “Parties”), a Delaware corporation.
SEPARATION AND DISTRIBUTION AGREEMENT BY AND BETWEEN MERCK & CO., INC. AND ORGANON & CO. DATED AS OF JUNE [ ], 2021Separation and Distribution Agreement • April 14th, 2021 • Organon & Co. • Pharmaceutical preparations • Delaware
This SEPARATION AND DISTRIBUTION AGREEMENT, dated as of June , 2021, is by and between Merck & Co., Inc., a New Jersey corporation (“Merck”), and Organon & Co., a Delaware corporation (“Organon”) (each a “Party” and together, the “Parties”).
AMENDMENT NO. 6 TO DEVELOPMENT AND COMMERCIALIZATION AGREEMENTDevelopment and Commercialization Agreement • April 14th, 2021 • Organon & Co. • Pharmaceutical preparations
This Amendment No. 6 to Development and Commercialization Agreement (this “Amendment No. 6”) is effective as of December 19, 2018 (the “Amendment Date”) and is entered into by and between:
AMENDMENT NO. 1 TO DEVELOPMENT AND COMMERCIALIZATION AGREEMENTDevelopment and Commercialization Agreement • April 14th, 2021 • Organon & Co. • Pharmaceutical preparations
This Amendment No. 1 to Development and Commercialization Agreement (this “Amendment”) is effective as of July 21, 2014 (the “Amendment Date”), and is entered into by and between SAMSUNG BIOEPIS CO., LTD., a corporation organized and existing under the laws of the Republic of Korea (“Samsung”) and MERCK SHARP & DOHME CORP., a corporation organized and existing under the laws of the State of New Jersey, USA (“Merck”).
AMENDMENT NO. 5 TO DEVELOPMENT AND COMMERCIALIZATION AGREEMENTDevelopment and Commercialization Agreement • April 14th, 2021 • Organon & Co. • Pharmaceutical preparations
This Amendment No. 5 to Development and Commercialization Agreement (this “Amendment No. 5”) is effective as of October 15, 2018 (the “Amendment Effective Date”) and is entered into by and between:
AMENDMENT NO. 2 TO DEVELOPMENT AND COMMERCIALIZATION AGREEMENTDevelopment and Commercialization Agreement • April 14th, 2021 • Organon & Co. • Pharmaceutical preparations
This Amendment No. 2 to Development and Commercialization Agreement (this “Amendment No. 2”) is effective as of Aug 2, 2017 (the “Amendment Date”), and is entered into by and between SAMSUNG BIOEPIS CO., LTD., a corporation organized and existing under the laws of the Republic of Korea (“Samsung”) and MERCK SHARP & DOHME CORP., a corporation organized and existing under the laws of the State of New Jersey, USA (“Merck”).
AMENDMENT NO. 3 TO DEVELOPMENT AND COMMERCIALIZATION AGREEMENTDevelopment and Commercialization Agreement • April 14th, 2021 • Organon & Co. • Pharmaceutical preparations
This Amendment No. 3 to Development and Commercialization Agreement (this “Amendment No. 3) is effective as of October 1, 2017 (the “Amendment Effective Date”) and is entered into by and between:
DEVELOPMENT AND COMMERCIALIZATION AGREEMENT by and between SAMSUNG BIOEPIS CO., LTD. and MERCK SHARP & DOHME CORP.Development and Commercialization Agreement • April 14th, 2021 • Organon & Co. • Pharmaceutical preparations • New York
This Development and Commercialization Agreement (this “Agreement”) is effective as of February 18, 2013 (the “Effective Date”), and is entered into by and between SAMSUNG BIOEPIS CO., LTD., a corporation organized and existing under the laws of the Republic of Korea (“Samsung”) and MERCK SHARP & DOHME CORP., a corporation organized and existing under the laws of the State of New Jersey, USA (“Merck”).
AMENDMENT NO. 7 TO DEVELOPMENT AND COMMERCIALIZATION AGREEMENTDevelopment and Commercialization Agreement • April 14th, 2021 • Organon & Co. • Pharmaceutical preparations
This Amendment No. 7 to Development and Commercialization Agreement (this “Amendment No. 7) is effective as of May 15, 2020 (the “Amendment Effective Date”) and is entered into by and between:
AMENDMENT NO. 4 TO DEVELOPMENT AND COMMERCIALIZATION AGREEMENTDevelopment and Commercialization Agreement • April 14th, 2021 • Organon & Co. • Pharmaceutical preparations
This Amendment No. 4 to Development and Commercialization Agreement (this “Amendment No. 4”) is effective as of September 1, 2018 (the “Amendment Effective Date”) and is entered into by and between:
